| Assessment Status | Rapid review complete |
| HTA ID | - |
| Drug | Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate |
| Brand | Delstrigo® |
| Indication | For the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, lamivudine or tenofovir |
| Assessment Process | |
| Rapid review commissioned | 06/12/2018 |
| Rapid review completed | 16/01/2019 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that Destrigo® be considered for reimbursement.* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement; February 2019
